WallStSmart

ePlus inc (PLUS)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ePlus inc generates 830% more annual revenue ($2.41B vs $258.90M). PLUS leads profitability with a 5.5% profit margin vs -15.5%. PLUS earns a higher WallStSmart Score of 72/100 (B).

PLUS

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 5.5Value: 8.7Quality: 6.8
Piotroski: 4/9Altman Z: 2.99

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PLUSUndervalued (+43.4%)

Margin of Safety

+43.4%

Fair Value

$148.15

Current Price

$84.69

$63.46 discount

UndervaluedFair: $148.15Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PLUS5 strengths · Avg: 8.0/10
PEG RatioValuation
0.858/10

Growing faster than its price suggests

P/E RatioValuation
14.9x8/10

Attractively priced relative to earnings

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
24.6%8/10

Revenue surging 24.6% year-over-year

EPS GrowthGrowth
46.3%8/10

Earnings expanding 46.3% YoY

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

PLUS2 concerns · Avg: 2.5/10
Profit MarginProfitability
5.5%3/10

5.5% margin — thin

Free Cash FlowQuality
$-88.86M2/10

Negative free cash flow — burning cash

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : PLUS

The strongest argument for PLUS centers on PEG Ratio, P/E Ratio, Price/Book. Revenue growth of 24.6% demonstrates continued momentum. PEG of 0.85 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : PLUS

The primary concerns for PLUS are Profit Margin, Free Cash Flow.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

PLUS profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PLUS scores higher overall (72/100 vs 41/100) and 24.6% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ePlus inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

ePlus inc. The company is headquartered in Herndon, Virginia.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?